BARDA awards Summit up to $62M for CDI candidate

Summit Therapeutics plc (LSE:SUMM; NASDAQ:SMMT) said HHS's Biomedical Advanced Research and Development Authority (BARDA) awarded the biotech up to $62 million to develop ridinilazole to treat Clostridium difficile infection. The contract includes $32 million up front; the remainder can be triggered by option exercises...